Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is ...
Ideaya Biosciences has made a key hire in anticipation of the launch of its first drug, securing the services of an executive ...
GlobalData on MSN2d
Gilead’s Livdelzi shows promise in PBC clinical trialThe analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.
Gilead Sciences, a Bay Area-headquartered biotech and pharmaceutical company, is laying off 104 workers in Foster City, with ...
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
Fintel on MSN4d
Wolfe Research Initiates Coverage of Gilead Sciences (GILD) with Outperform RecommendationFintel reports that on November 15, 2024, Wolfe Research initiated coverage of Gilead Sciences (NasdaqGS:GILD) with a ...
Try Now>> See today’s best-performing stocks on TipRanks >> Read More on GILD: Gilead Sciences NewsMORE Related Stocks Indices Commodities Currencies Stocks ...
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $88.4 which represents a decrease of $-3.71 or -4.03% from the prior close of $92.11. The stock opened at $91.71 and ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback